<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38631816</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1757-790X</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>17</Day></PubDate></JournalIssue><Title>BMJ case reports</Title><ISOAbbreviation>BMJ Case Rep</ISOAbbreviation></Journal><ArticleTitle>Long-term cognitive effects of COVID-19 studied with repeated neuropsychological testing.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e256711</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bcr-2023-256711</ELocationID><Abstract><AbstractText>COVID-19 has a wide range of clinical manifestations. Apart from respiratory symptoms, neurological manifestations and cognitive impairment are commonly seen. Due to lack of a clear consensus on the definition of long COVID a pragmatic approach of assessing change from neurological baseline has become prevalent. We present the case of a high functioning woman in her late 40s who had a mild course of acute illness but developed cognitive difficulties. No organic causes for her cognitive difficulties were found. Neuropsychological testing showed impairment in right frontal lobe functioning. The patient showed a response to empirical treatment with Attention deficit hyperactivity disorder (ADHD) medications. Repeat neuropsychological testing 1 year later showed continued dysfunction in executive functioning. We present the details of her test findings and discuss the proposed pathophysiology behind neurocognitive effects of long COVID.</AbstractText><CopyrightInformation>&#xa9; BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Beverly</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Central Illinois Neuropsychological Services at A&amp;E Behavioral Healthcare Associates, Decatur, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Datey Chakrabarty</LastName><ForeName>Ashima</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Medicine-Psychiatry, Department of Psychiatry, Southern Illinois University School of Medicine, Springfield, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakrabarty</LastName><ForeName>Arindam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Southern Illinois University School of Medicine, Springfield, Illinois, USA achakrabarty23@siumed.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Case Rep</MedlineTA><NlmUniqueID>101526291</NlmUniqueID><ISSNLinking>1757-790X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="Y">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">memory disorders</Keyword><Keyword MajorTopicYN="N">memory disorders (psychiatry)</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>18</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>17</Day><Hour>21</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38631816</ArticleId><ArticleId IdType="pmc">PMC11029200</ArticleId><ArticleId IdType="doi">10.1136/bcr-2023-256711</ArticleId><ArticleId IdType="pii">17/4/e256711</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Garg M, Maralakunte M, Garg S, et al. . &#x201c;The conundrum of &#x201c;long-COVID-19&#x201d;: a narrative review&#x201d;. IJGM 2021;Volume 14:2491&#x2013;506. 10.2147/IJGM.S316708</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S316708</ArticleId><ArticleId IdType="pmc">PMC8214209</ArticleId><ArticleId IdType="pubmed">34163217</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavares-J&#xfa;nior JWL, de Souza ACC, Borges JWP, et al. . COVID-19 associated cognitive impairment: a systematic review. Cortex 2022;152:77&#x2013;97. 10.1016/j.cortex.2022.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cortex.2022.04.006</ArticleId><ArticleId IdType="pmc">PMC9014565</ArticleId><ArticleId IdType="pubmed">35537236</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JH, Lin JJ, Doernberg M, et al. . Assessment of cognitive function in patients after COVID-19 infection. JAMA Netw Open 2021;4:e2130645. 10.1001/jamanetworkopen.2021.30645</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.30645</ArticleId><ArticleId IdType="pmc">PMC8536953</ArticleId><ArticleId IdType="pubmed">34677597</ArticleId></ArticleIdList></Reference><Reference><Citation>Crivelli L, Palmer K, Calandri I, et al. . Changes in cognitive functioning after COVID-19: A systematic review and meta-analysis. Alzheimers Dement 2022;18:1047&#x2013;66. 10.1002/alz.12644</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12644</ArticleId><ArticleId IdType="pmc">PMC9073922</ArticleId><ArticleId IdType="pubmed">35297561</ArticleId></ArticleIdList></Reference><Reference><Citation>Miskowiak KW, Johnsen S, Sattler SM, et al. . Cognitive impairments four months after COVID&#x2010;19 hospital discharge: pattern, severity and association with illness variables. Eur Neuropsychopharmacol 2021;46:39&#x2013;48. 10.1016/j.euroneuro.2021.03.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2021.03.019</ArticleId><ArticleId IdType="pmc">PMC8006192</ArticleId><ArticleId IdType="pubmed">33823427</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellucci G, Ballerini C, Mechelli R, et al. . SARS&#x2010;Cov&#x2010;2 Meta&#x2010;Interactome suggests disease&#x2010;specific, autoimmune pathophysiologies and therapeutic targets. F1000Res 2020;9:992. 10.12688/f1000research.25593.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.25593.1</ArticleId><ArticleId IdType="pmc">PMC7791351</ArticleId><ArticleId IdType="pubmed">33456761</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier J, Bertrand P, Poirier J, et al. . Apolipoprotein E polymorphism and Alzheimer&#x2019;s disease. The Lancet 1993;342:697&#x2013;9. 10.1016/0140-6736(93)91705-Q</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0140-6736(93)91705-Q</ArticleId><ArticleId IdType="pubmed">8103819</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanou M-I, Palaiodimou L, Bakola E, et al. . Neurological manifestations of long-COVID syndrome: a narrative review. Ther Adv Chronic Dis 2022;13. 10.1177/20406223221076890</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20406223221076890</ArticleId><ArticleId IdType="pmc">PMC8859684</ArticleId><ArticleId IdType="pubmed">35198136</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization (WHO). A clinical case definition of post COVID-19 condition by A Delphi consensus, 6
October
2021. Available: https://www.who.int/docs/default-source/ coronaviruse/corrigendum-2021.1-post-covid-19-clinical-case-definition-2021-10-06-corr-2021-10-06-en.pdf?sfvrsn=1ebb697c_5
</Citation></Reference><Reference><Citation>
World Health Organization (WHO) . Emergency use ICD codes for COVID-19 disease outbreak. 2020. Available: https://www.who.int/standards/classifications/classification-of-diseases/emergency-use-icd-codes-for-covid-19-diseaseoutbreak
</Citation></Reference><Reference><Citation>Hutson PH, Pennick M, Secker R. Preclinical pharmacokinetics, pharmacology and toxicology of Lisdexamfetamine: a novel d-amphetamine pro-drug. Neuropharmacology 2014;87:41&#x2013;50. 10.1016/j.neuropharm.2014.02.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2014.02.014</ArticleId><ArticleId IdType="pubmed">24594478</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubair AS, McAlpine LS, Gardin T, et al. . Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 2020;77:1018&#x2013;27. 10.1001/jamaneurol.2020.2065</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.2065</ArticleId><ArticleId IdType="pmc">PMC7484225</ArticleId><ArticleId IdType="pubmed">32469387</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazhenets G, Schroeter N, Bormann T, et al. . Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. J Nucl Med 2021;62:910&#x2013;5. 10.2967/jnumed.121.262128</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.121.262128</ArticleId><ArticleId IdType="pmc">PMC8882885</ArticleId><ArticleId IdType="pubmed">33789937</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj E, Campion JY, Dudouet P, et al. . (18)F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging 2021;48:2823&#x2013;33. 10.1007/s00259-021-05215-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05215-4</ArticleId><ArticleId IdType="pmc">PMC7837643</ArticleId><ArticleId IdType="pubmed">33501506</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanberg N, Simr&#xe9;n J, Ed&#xe9;n A, et al. . Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. EBioMedicine 2021;70:103512. 10.1016/j.ebiom.2021.103512</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103512</ArticleId><ArticleId IdType="pmc">PMC8320425</ArticleId><ArticleId IdType="pubmed">34333238</ArticleId></ArticleIdList></Reference><Reference><Citation>Taribagil P, Creer D, Tahir H. Long COVID' syndrome. BMJ Case Rep 2021;14:e241485. 10.1136/bcr-2020-241485</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2020-241485</ArticleId><ArticleId IdType="pmc">PMC8057566</ArticleId><ArticleId IdType="pubmed">33875508</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer KP, Steele AK, Soper MK, et al. . Physical therapy management of an individual with post-COVID syndrome: A case report. Phys Ther 2021;101:pzab098. 10.1093/ptj/pzab098</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ptj/pzab098</ArticleId><ArticleId IdType="pmc">PMC7989151</ArticleId><ArticleId IdType="pubmed">33735380</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellmuth J, Barnett TA, Asken BM, et al. . Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. J Neurovirol 2021;27:191&#x2013;5. 10.1007/s13365-021-00954-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-021-00954-4</ArticleId><ArticleId IdType="pmc">PMC7852463</ArticleId><ArticleId IdType="pubmed">33528824</ArticleId></ArticleIdList></Reference><Reference><Citation>Victor MM, M&#xfc;ller Haas L, Grevet EH, et al. . Successful treatment of post-COVID-19 ADHD-like syndrome: a case report. J Atten Disord 2023;27:1092&#x2013;8. 10.1177/10870547231168338</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10870547231168338</ArticleId><ArticleId IdType="pmc">PMC10102822</ArticleId><ArticleId IdType="pubmed">37052263</ArticleId></ArticleIdList></Reference><Reference><Citation>Fesharaki-Zadeh A, Lowe N, Arnsten AFT. Clinical experience with the &#x391;2A-adrenoceptor agonist, Guanfacine, and N-Acetylcysteine for the treatment of cognitive deficits in &#x201c;long-Covid19. Neuroimmunology Reports 2023;3:100154. 10.1016/j.nerep.2022.100154</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nerep.2022.100154</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>